Typical HBsAg escape mutation | Mutation patterns | n (%) | Combined mutations | Mutation patterns | n (%) |
---|---|---|---|---|---|
Immune escape | sY100C, sI110L, sP120L/R, sTl23N, sT127L, sP127T, sA128V, sT131N, sS132P, sY134F/H, sT140I/S, sS143T, sD144E, sS144T, sP210S | 16 (24) | Immune response -vaccine | sI110L + sS193L | 1 (1.5) |
Vaccine escape | sT126I, sD144A/E, sG145A/R, S193L, sP210T | 7 (10) | Vaccine-HBIg | sP120L + sT123N + sT126I + sA128V + sY134H + sD144E + sG145A | 1 (1.5) |
HBIg | sT118A, sP120T, sD144A/E, sG145A/E/R | 4 (6) | Immune response -HBIg | sT118A + sP127T | 1 (1.5) |
Diagnostic escape | sT118A, sT131I, sP120T, sC121Y, sD144A, sG145R | 3 (4) | Immune response-vaccine-HBIg | sI110L + sP120T + sD144A + sG145R sP120R + sC121Y, sT131I + sS132P | 1 (1.5) |
Total | 30 (44) | 6 (9) |
Variable | Study Group |
---|---|
Patient, n | 100 |
Gender, F/M, n (%) | 13 (13%)/87 (87%) |
Age, median year (range) | 35 (18-65) |
Nationality, region/country, n (%) | |
| |
Turkey | 43 (63) |
Northern Cyprus | 14 (21) |
Pakistan | 3 (4) |
China | 3 (4) |
Turkmenistan | 3 (4) |
Syria | 1 (2) |
Georgia | 1 (2) |
| |
Nigeria | 28 (97) |
Benguela | 1 (3) |
| |
Mexican | 1 (100) |
| |
Azerbaijan | 1 (50) |
Bulgaria | 1 (50) |
Anti HBc IgG positivity, n (%) | 96 (96) |
HBeAg positivity, n (%) | 5 (5) |
ALT (average ± SD) (U/L) | 23 ± 19 |
AST (average ± SD) (U/L) | 28 ± 19 |
HBV DNA median IU/ml (range) | 1.0 + E7 |
Genotype/subgenotype of HBV, n (%) | |
D1 | 48 (70.6) |
D2 | 4 (5.9) |
D3 | 1 (1.5) |
A1 | 5 (7.3) |
A2 | 2 (2.9) |
Treatment status, n (%) | |
Naive | 100 (100%) |
Under treatment | - |
HBV virion | Mutation characteristic | Mutation pattern | Nucleos(t)ide analogues | n (%) |
---|---|---|---|---|
Primary resistance mutation | ND | ND | - | |
Compensatory mutation | rtL91I | LdT related | 25 (36.8) |